STAT reports that four major drugmakers allegedly paid tens of millions of dollars to middlemen to supply lifesaving drugs to Russian government entities. The report did not name the companies or provide further details on the transactions or their timing.
This raises concerns for pharmaceutical executives about compliance and reputational risk, especially in jurisdictions with sanctions or heightened scrutiny. Firms may need to review third-party controls and due diligence processes to address potential exposure.
